/
Information BioScience Health Innovations Inc. ( we, us, the Company ) was incorporated in the State of Nevada on July 8, 2019 with the name Nowtransit, Inc. and we changed our name to BioScience Health Innovations Inc. on February 21, 2025. Investors should carefully consider the following Risk Factors before deciding whether to invest in the Company.
$4.08
+$0.04 (+1.01%)
EOD Jul 17, 2026
12.64% operating margin is respectable but not wide. ROIC at 55.53%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue up 208.3% YoY with margins expanding 7.9pp.
At 136x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
136.0x earnings. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$5M
▲ +208.3% YoY
Net Income (TTM)
-$15K
▲ +638.0% YoY
Op. Margin
1.20%
▲ +7.9pp YoY
ROIC
2.79%
▲ +39.1pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$708K
▲ +642.5% YoY
Net Debt
-$685K
Net Cash Position
Cash & Equiv.
$1M
Continue Research
At a P/E of 136.0, BioScience Health Innovations (BHIC)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, BioScience Health Innovations scores 54/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
BioScience Health Innovations scores 54 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 1.2% operating margin and a 2.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh BHIC's valuation and scores 54/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.